Piramal Pharma Share Price Target 2025: Will It Reach ₹300?
Piramal Pharma (NSE: PPLPHARMA) is currently trading in the ₹204–₹206 range as of August 1, 2025. With neutral RSI, mixed signals from moving averages, and resistance around ₹210, the stock appears to be in a consolidation phase. However, breakout potential remains alive for 2025, with analysts predicting a target range between ₹260 and ₹300 based on technical trends and pharma sector momentum.
Current Stock Highlights
Indicator | Value |
---|---|
Current Price | ₹190.50 |
52-Week High/Low | ₹307.85 / ₹166.00 |
Market Cap | ₹25.17KCr |
Volume | Stable / Low |
Sector | Pharma / CDMO |
Technical Analysis (As of August 1, 2025)
-
RSI (Relative Strength Index): 50.41 → Neutral zone
-
MACD: +0.51 → Mildly bullish momentum
-
20-Day EMA: ₹205.65 → Close to current price
-
50-Day MA: ₹203.81 (Buy Signal)
-
200-Day MA: ₹224.60 (Still below, indicating resistance)
-
Immediate Resistance: ₹210–₹212
-
Support Zone: ₹200–₹202
These indicators suggest the stock may be poised for a breakout, but needs strong volume confirmation.
Piramal Pharma Share Price Target 2025
Outlook | Price Target (₹) | Technical Condition |
---|---|---|
Bullish | ₹280 – ₹300 | Break above ₹210 with strong volume |
Base Case | ₹260 – ₹280 | Sustained momentum with pharma tailwinds |
Bearish | ₹200 – ₹215 | Rejection at ₹210, sector underperforms |
Key Growth Drivers
-
CDMO Expansion: Strong growth in custom development and manufacturing contracts
-
Generics Business: Contribution from inhalation and injectable drugs
-
Hospital Solutions: Margin improvement potential
-
New Product Pipeline: Portfolio expansion in complex generics
Risks to Watch
-
High Valuation: Current P/E ~300x could limit fresh buying
-
Overhead Resistance: ₹210–₹212 needs strong breakout
-
Pharma Sector Regulation: Domestic and global compliance factors
-
Muted Volume: Lack of institutional interest in short term
Expert Opinion
According to analysts at Trendlyne and TipRanks, the next major trend will depend on earnings visibility and momentum above ₹210. If crossed, the stock can quickly aim for ₹260+ in the coming quarters.
Piramal Pharma looks technically neutral but fundamentally promising. Investors should watch the ₹210 resistance zone closely. A breakout could signal a strong move toward ₹280–₹300 by end of 2025.
Long-term investors may consider accumulating on dips near ₹200 if broader pharma sentiment supports the stock.